Abstract
The antifibromatogenic potency of deoxycorticosterone—prevention of œstrogen-induced abdominal fibroids—diminishes through the substitution O=C11 (Kendall's compound A) and especially through OH– –C17 (Reichstein's compound S)1. The anti-fibromatogenic potency of cortisone,which differs from deoxycorticosterone by both these substitutions, is also strikingly diminished; there were fibroids even with as much as 1,000 µgm. of cortisone acetate per day. But, on the other hand, there apparently was some antifibromatogenic activity of compound F, or 17-hydroxy-corticosterone (OH– –C17 and OH—C11); we had thus to raise the question of a ‘protective’ action of OH—C11 against OH– –C17. However, in view of the variations of the fibrous tumoral effect met with in similar experiments, and especially in view of the small number of experiments performed with compound F, the conclusion as to the supposed ‘protective’ action of OH—C11 against OH– –C17 remained doubtful1. In the meantime, we have been able to settle this question in what seems to be a definite manner, thanks to the kindness of Messrs. Merck and Co., who put at our disposal the necessary quantities of compound F acetate.
Similar content being viewed by others
Article PDF
References
Mardones, E., Iglesias, R., Fuenzalida, F., Bruzzone, S., and Lipschutz, A., Nature, 170, 917 (1952).
Stock, C. C., Ciba Found. Coll. Endocrinol., 1, 135 (1952).
Lipschutz, A., Mardones, E., Iglesias, R., Fuenzalida, F., and Bruzzone, S., Science, 116, 448 (1952).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
MARDONES, E., IGLESIAS, R. & LIPSCHUTZ, A. Structural Features of Antitumorigenic Corticoids. Nature 171, 1026 (1953). https://doi.org/10.1038/1711026a0
Issue Date:
DOI: https://doi.org/10.1038/1711026a0
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.